Updated:
Avlar BioVentures
Avlar BioVentures is a single-family office investing exclusively in translational biotech and health-technology companies, from preclinical to Series A.
Avlar BioVentures
Avalar BioVentures is a biotechnology venture capital company with over Euro150 million under management. The firm invests in seed and early-stage biopharmaceutical, medtech, and biotechnology opportunities through its funds, including Avlar BioVentures Fund I, Avlar BioVentures Fund II, and the First Cambridge Gateway Fund. Avalar BioVentures has made 26 investments and achieved 8 portfolio exits.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What does Avlar BioVentures invest in?
Avlar concentrates exclusively on life sciences, deploying into biotech therapeutics, diagnostics, medical devices, and digital-health platforms. The firm focuses on early-stage, translational opportunities — typically preclinical through Series A — where the underlying science addresses a well-defined clinical need.
How is Avlar BioVentures structured relative to the family's other assets?
Avlar operates as the dedicated life-science investment vehicle for a single-family pool. It is not a generalist office that adds biotech as one of many allocations; its mandate is effectively monoline, making it operate more like an internal venture-capital arm than a diversified family office.
Does Avlar BioVentures invest directly or through funds?
The firm uses a hybrid approach: it makes direct equity investments in early-stage life-science companies and also commits capital to external venture funds focused on biotechnology and healthcare. This allows exposure to both concentrated single-company bets and broader portfolio diversification.
Who runs investment decisions at Avlar BioVentures?
The investment principals at Avlar have not been publicly identified. The firm maintains no active LinkedIn presence and its website provides only a domain placeholder, suggesting decisions are made by a tightly held group — likely the family principals themselves or a small internal investment team.
Does Avlar BioVentures maintain a public presence or accept outside capital?
No. Avlar BioVentures has no public-facing website content, no active LinkedIn company page, and no known track record of fundraising from external investors. It appears to be a private deployment vehicle dedicated solely to the family's proprietary capital.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: